ARROWHEAD RESEARCH (HDP1 BE) stock market data APIs
€32.1004
0(0%)
as of October 24, 2025
Try our APIs with
free plan!
ARROWHEAD RESEARCH Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for HDP1.BE.
Prev. Close
32.1004
Open
32.1004
High
32.1004
Low
32.1004
52 wk Range
8.77-32.88
Market Cap
6 485 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARROWHEAD RESEARCH data using free add-ons & libraries
Get ARROWHEAD RESEARCH Fundamental Data
ARROWHEAD RESEARCH Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARROWHEAD RESEARCH News
New
How Arrowhead’s Evolving Story Is Shaping Analyst Views and Fair Value Targets
Arrowhead Pharmaceuticals has seen its consensus analyst price target increase from $45 to $47.50 per share, reflecting growing confidence in the company's strategy and market positioning. This positi...
Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
DelveInsight Business Research LLP The complement 3 glomerulopathy market is poised for steady growth, driven by increasing disease awareness, advances in complement pathway research, and rising diag...
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
PASADENA, Calif., October 21, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announ...
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- ARO-DIMER-PA is designed to selectively silence the expression of two genes with a single RNAi molecule using Arrowhead’s proprietary TRiMTM technology - In preclinical studies ARO-DIMER-PA poten...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
